Solid Biosciences is a life sciences company based in Charlestown, MA, dedicated to advancing genetic medicines for neuromuscular and cardiac rare diseases. With a diverse pipeline of gene therapy candidates and programs, including treatments for Duchenne muscular dystrophy, catecholaminergic polymorphic ventricular tachycardia, and Friedreich's ataxia, Solid Biosciences aims to improve the daily lives of patients affected by these devastating conditions.
Founded by individuals directly impacted by these diseases, Solid Biosciences brings together experts in science, technology, disease management, and care to drive innovation and develop effective treatments. Committed to patient-focused research and development, the company is focused on advancing its portfolio of neuromuscular and cardiac programs to address the urgent needs of those living with these rare diseases.
Generated from the website